LYON, France, July 18, 2023 – POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases , today announces its participation in the 2nd Annual HC Wainwright 2nd Annual Kidney Conference, which will be held virtually on Tuesday, July 25, 2023.
Thomas Kuhn, Chief Executive Officer and members of Poxel’s management team, will be available for one-to-one virtual interviews on July 25, 2023. A virtual Company presentation is scheduled the same day at 3:30 p.m. New York) and will focus on PXL770, a novel direct activator of adenosine monophosphate-activated protein kinase (AMPK), for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
To receive information from POXEL in real time, send a request to [email protected].